Edition:
United States

Abeona Therapeutics Inc (ABEO.OQ)

ABEO.OQ on NASDAQ Stock Exchange Capital Market

12.50USD
16 Feb 2018
Change (% chg)

$0.45 (+3.73%)
Prev Close
$12.05
Open
$11.85
Day's High
$13.15
Day's Low
$11.65
Volume
398,849
Avg. Vol
270,722
52-wk High
$22.70
52-wk Low
$4.55

Select another date:

Mon, Feb 12 2018

BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns

* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE

BRIEF-Abeona Therapeutics Says Gene Therapy ABO-101 Is Well Tolerated

* ABEONA THERAPEUTICS REPORTS ON INITIAL SAFETY AND BIOPOTENCY SIGNALS IN MPS IIIB GENE THERAPY CLINICAL TRIAL

BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder

* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA

BRIEF-Abeona Q3 loss per share $0.13

* Abeona reports third quarter 2017 financial results and recent business highlights

BRIEF-Abeona Therapeutics prices offering of five million shares at $16 per share

* Pricing underwritten public offering of five million shares of common stock at a public offering price of $16.00 per share​ Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics announces public offering of common stock

* Abeona Therapeutics announces public offering of common stock Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics to receive $13.85 mln of grants for development of Sanfilippo gene therapy programs​

* Abeona Therapeutics Inc - ‍nine global foundations collaborate to grant $13.85 million for continued advancement of lead Sanfilippo gene therapy programs​ Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics enrolls first two patients in phase 1/2 clinical trial in MPS IIIA

* Abeona Therapeutics enrolls first two patients in pivotal expansion of phase 1/2 clinical trial in MPS IIIA

BRIEF-ABEONA ANNOUNCES TOP-LINE ONE YEAR DATA FROM ABO-102 MPS IIIA TRIAL

* ABEONA ANNOUNCES TOP-LINE ONE YEAR DATA FROM ABO-102 MPS IIIA TRIAL AT ARM’S CELL & GENE MEETING ON THE MESA

BRIEF-Viking Global Investors reports 5.6 percent passive stake in Abeona Therapeutics

* Viking Global Investors Lp reports 5.6 percent passive stake in Abeona Therapeutics Inc ‍​as of Sept 22 - SEC filing Source: (http://bit.ly/2yEgWSq) Further company coverage:

Select another date: